About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  Home
  
     
 
Disclosure to Stock Exchange

  January 2017
11 Jan  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Trastuzumab Download Pdf

  December 2016
27 Dec  Journal of the American Medical Association  (JAMA) Publishes Mylan and Biocon's  Proposed Biosimilar Trastuzumab Phase 3  Data Download Pdf
20 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
17 Dec  Transfer of shares to Investor Education  and Protection Fund Download Pdf
16 Dec  Disclosure under Regulation 30 of SEBI  (LODR) Regulations, 2015 - Change in Key  Managerial Personnel Download Pdf
13 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
13 Dec  Disclosure under Regulation 30 of SEBI  (LODR) Regulations, 2015 Download Pdf
06 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  November 2016
29 Nov  Biocon's Novel Diabetes Education Initiative  for Medical Practitioners 'ABIDE' Awarded  by RSSDI Download Pdf
22 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
17 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
15 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
11 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
09 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
08 Nov  Mylan and Biocon Announce U.S. FDA  Submission for Proposed Biosimilar  Trastuzumab Download Pdf
03 Nov  Mylan and Biocon Announce Regulatory  Submission for Insulin Glargine Accepted  for Review by European Medicines Agency Download Pdf
  October 2016
24 Oct  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
20 Oct  Unaudited Financial Results for the quarter  and period ended Sep. 30, 2016
Download Pdf
  September 2016
29 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
23 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
19 Sep  Biocon Appoints Suresh Subramanian as  Head of Branded Formulations (India)  Business Download Pdf
14 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
07 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
01 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  August 2016
26 Aug  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
25 Aug  Mylan and Biocon Announce Regulatory  Submission for Proposed Biosimilar  Trastuzumab Accepted for Review by  European Medicines Agency Download Pdf
24 Aug  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
17 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
9 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
2 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
  July 2016
28 July  Biocon Initiates "Ek Prayaas" Nationwide  Awareness Program on Hepatitis C Download Pdf
21 July  Biocon Reports a Strong Q1FY17
 Revenues at Rs 952 Crore, up by 11 %;  EBITDA Up 15% to Rs 271 Crore
 Net Profit Up 17% at Rs 147 Crore
Download Pdf
21 July  Mylan & Biocon Announce Regulatory  Submission for Proposed Biosimilar  Pegfilgrastim Accepted for Review by  European Medicines Agency Download Pdf
15 July  Biocon's Insulin Glargine Launched in Japan Download Pdf
  June 2016
27 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
24 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
23 Jun  Biocon, Quark Announce Initiation of Pivotal  Phase II/III Study of QPI-1007 in Rare Eye  Disease in India Download Pdf
22 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
16 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
10 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
04 Jun  Mylan and Biocon to Present Phase 3  Trastuzumab Biosimilar Data at the  American Society of Clinical Oncology  (ASCO) Annual Meeting Download Pdf
03 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
01 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
  May 2016
30 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
26 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
26 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
18 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
12 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
5 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
3 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf

  April 2016
26 Apr  Biocon Q4FY16 Net Profit at Rs 361 Cr  Revenue Crosses Rs 1,000 Cr; Up 17% FY  16 Revenues up 14% at Rs 3,570 Cr  Net  Profit at Rs 896 CrDownload Pdf
26 Apr  Intimation Regarding Appointment of  Director Download Pdf

  March 2016
29 Mar  Intimation regarding Analysts/Institutional
 Investors Meet
Download Pdf
28 Mar  Biocon's Insulin Glargine Receives
 Regulatory Approval in Japan
Download Pdf
23 Mar  Intimation regarding Analysts/Institutional
 Investors Meet
Download Pdf
17 Mar  Biocon Inks Co-Development &
 Commercialization Agreement with
 Lab PiSA for rh-Insulin in USA
Download Pdf
17 Mar  Agreement for development and
 commercialisation of rh-Insulin for US
 market
Download Pdf
15 Mar  Intimation regarding Analysts/Institutional
 Investors Meet
Download Pdf
11 Mar  Declaration of Interim Dividend Download Pdf
08 Mar  Intimation regarding Analysts/Institutional
 Investors Meet
Download Pdf
04 Mar  Intimation regarding Analysts/Institutional
 Investors Meet
Download Pdf

  February 2016
24 Feb  Intimation regarding Analysts/Institutional
 Investors Meet
Download Pdf
15 Feb  Press Release: 
 Biocon Gets its First Generic Formulation
 Approval in EU; On Track to Launch
 Rosuvastatin Tablets in FY 17
Download Pdf
03 Feb  Press Release: 
 Biocon Academy Introduces First Of Its
 Kind Career Advancement Program In
 'Quality Control Microbiology' in
 Collaboration with BITS Pilani
Download Pdf

  January 2016
21 Jan  Press Release: 
 Biocon Q3FY16 Net Profit Up 13% at
 Rs 103 Crore
Download Pdf
21 Jan  Press Release: 
 Biocon Announces Data from Key Studies
 for Insulin Tregopil
Download Pdf

  December 2015
24 Dec  Press Release: 
 Biocon Introduces CIMIVIR-L for
 Hepatitis-C in India
Download Pdf
09 Dec  Press Release: 
 NeoBiocon Partners with Novartis to offer
 Vildagliptin for Diabetics in UAE
Download Pdf
 
     
 
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved